Clinical · Molecular biology · Bioinfo & AI
Identification of PD-1-Related Genes as Prognostic Biomarkers in Lung Adenocarcinoma
Summary
This study developed a robust prognostic model for lung adenocarcinoma (LUAD) by focusing on PD-1-related genes. Utilizing advanced bioinformatics analyses and in vitro validations, a nine-gene risk model (ADA2, CD53, HLA-DMA, ITGAX, MYO1F, NCKAP1L, PTPRC, RENBP, TNFAIP8L2) was constructed. This model demonstrated strong predictive performance, stratifying patients into high- and low-risk groups with distinct prognoses. High-risk patients exhibited a worse prognosis and lower immune infiltration, while drug sensitivity analyses identified specific candidate therapeutic agents for each group.
Critical appraisal
Clinical. This study proposes a nine-gene prognostic model for lung adenocarcinoma, capable of stratifying patients into high- and low-risk groups with distinct prognoses. The model’s robust predictive performance, evaluated by high AUC values in time-dependent ROC analysis, suggests potential for personalized therapeutic strategies. While promising, this model requires prospective validation in independent clinical cohorts before clinical application. If validated, it could serve as a prognostic biomarker to guide treatment decisions and justify clinical trials targeting high-risk patients, with a potential clinical impact within 3-5 years.
Molecular biology. The discovery of a nine-gene prognostic signature (ADA2, CD53, HLA-DMA, ITGAX, MYO1F, NCKAP1L, PTPRC, RENBP, TNFAIP8L2) related to PD-1 represents a significant advance. Technologies used include transcriptomic analyses (WGCNA, limma) for differentially expressed gene identification and in vitro functional validations via Western blot, CCK-8, and migration/invasion assays (wound healing, Transwell). The functional validation of MYO1F and PTPRC, demonstrating their roles in LUAD cell migration and invasion, strengthens the biological validity of the signature. These genes could serve as novel therapeutic targets or predictive biomarkers for therapies based on the tumor microenvironment.
Bioinfo & AI. The study employed a robust integrative bioinformatics approach, combining the ESTIMATE algorithm for immune scores, WGCNA for gene module identification, and Cox regression analyses for prognostic model construction. Model performance was evaluated using time-dependent ROC curves (timeROC package). The integration of MCPcounter, ESTIMATE, and ssGSEA allowed for detailed tumor microenvironment characterization, while the pRRophetic package was used for drug sensitivity prediction. This multi-algorithmic approach is well-structured and reproducible, providing a framework for integrating omics data into risk stratification and therapeutic response prediction, potentially applicable in clinical workflows for precision medicine.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology